Oruka Therapeutics expands ORKA-001 license to include IBD; clinical dosing restrictions until 2028-2030

Oruka Therapeutics, Inc.

Oruka amended IL-23 license with Paragon to expand field to include inflammatory bowel disease (IBD).
Cannot dose ORKA-001 in combination IBD trial before June 1, 2028, or monotherapy before June 1, 2030.
If material transaction occurs (e.g., change of control), monotherapy restriction ends June 1, 2028.
Paragon's exclusivity for monospecific antibodies in IBD extended to October 11, 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.